Changes in asthma control, work productivity, and impairment with omalizumab: 5-year EXCELS study results

Allergy and Asthma Proceedings

Volumn 36, Issue 4, 2015, Pages 283-292

  Zazzali, James L ^a   Raimundo, Karina P ^a   Trzaskoma, Benjamin ^a   Rosén, Karin E ^a   Schatz, Michael ^b  

^a GENENTECH INC   (United States)

^b KAISER PERMANENTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

OMALIZUMAB; ANTIASTHMATIC AGENT;

ADULT; ALLERGIC ASTHMA; ARTICLE; ASTHMA; ASTHMA CONTROL TEST; CLINICAL EFFECTIVENESS; DAILY LIFE ACTIVITY; DIAGNOSTIC TEST; DISEASE CONTROL; DISEASE SEVERITY; DRUG SAFETY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PRODUCTIVITY; PROSPECTIVE STUDY; QUESTIONNAIRE; SCHOOL; WORK; WORK PRODUCTIVITY ACTIVITY IMPAIRMENT ASTHMA QUESTIONNAIRE; MIDDLE AGED; RISK FACTOR; SEVERITY OF ILLNESS INDEX; SICKNESS IMPACT PROFILE; TIME FACTOR; TREATMENT OUTCOME;

ADULT; ANTI-ASTHMATIC AGENTS; ASTHMA; EFFICIENCY; FEMALE; HUMANS; MALE; MIDDLE AGED; OMALIZUMAB; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SICKNESS IMPACT PROFILE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84938382120     PISSN: 10885412     EISSN: 15396304     Source Type: Journal    
DOI: 10.2500/aap.2015.36.3849     Document Type: Article

References (26)

1. From the Global Strategy for Asthma Management and Prevention, Global Imitative for Asthma (GINA) 2014. Available from: http://www.ginasthma.org/. Accessed April 2, 2015.
2. Bateman ED, Hurd SS, Barnes PJ, et al. Global strategy for asthma management and prevention: GINA executive summary. Eur Respir J 31:143-178, 2008.
3. National Asthma Education and Prevention Program Expert Panel Report 3 (EPR-3): Guidelines for the Diagnosis and Management of Asthma-Summary Report 2007. J Allergy Clin Immunol 120:S94-S138, 2007.
4. FDA, Omalizumab (Xolair) label. Available from: http://www.accessdata.fda.gov/drugsatfda-docs/label/2007/103976s5102lbl. pdf. Accessed April 2, 2015.
5. Bousquet J, Cabrera P, Berkman N, et al. The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma. Allergy 60:302-308, 2005.
6. Busse W, Corren J, Lanier BQ, et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 108: 184-190, 2001.
7. Holgate ST, Chuchalin AG, Hebert J, et al. Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma. Clin Exp Allergy 34:632-638, 2004.
8. Humbert M, Beasley R, Ayres J, et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 60: 309-316, 2005.
9. Niven R, Chung KF, Panahloo Z, et al. Effectiveness of omalizumab in patients with inadequately controlled severe persistent allergic asthma: An open-label study. Respir Med 102:1371-1378, 2008.
10. Soler M, Matz J, Townley R, et al. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J 18:254-261, 2001.
11. Franciosa JA. The potential role of community-based registries to complement the limited applicability of clinical trial results to the community setting: Heart failure as an example. Am J Manag Care 10:487-492, 2004.
12. Gutierrez LP, Koltowska-Haggstrom M, Jonsson PJ, et al. Registries as a tool in evidence-based medicine: Example of KIMS (Pfizer International Metabolic Database). Pharmacoepidemiol Drug Saf 17:90-102, 2008.
13. Long AA, Fish JE, Rahmaoui A, et al. Baseline characteristics of patients enrolled in EXCELS: A cohort study. Ann Allergy Asthma Immunol 103:212-219, 2009.
14. Eisner MD, Zazzali JL, Miller MK, et al. Longitudinal changes in asthma control with omalizumab: 2-year interim data from the EXCELS Study. J Asthma 49:642-648, 2012.
15. Schatz M, Sorkness CA, Li JT, et al. Asthma Control Test: Reliability, validity, and responsiveness in patients not previously followed by asthma specialists. J Allergy Clin Immunol 117:549-556, 2006.
16. Schatz M, Zeiger RS, Drane A, et al. Reliability and predictive validity of the Asthma Control Test administered by telephone calls using speech recognition technology. J Allergy Clin Immunol 119:336-343, 2007.
17. Nathan RA, Sorkness CA, Kosinski M, et al. Development of the asthma control test: A survey for assessing asthma control. J Allergy Clin Immunol 113:59-65, 2004.
18. Reilly MC, Zbrozek AS, and Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics 4:353-365, 1993.
19. Andreasson E, Svensson K, and Berggren F. The validity of the work productivity and activity impairment questionnaire for patients with asthma (WPAI-asthma): Results from a webbased study. Value Health 6:780, 2003.
20. Chen H, Blanc PD, Hayden ML, et al. Assessing productivity loss and activity impairment in severe or difficult-to-treat asthma. Value Health 11:231-239, 2008.
21. Schatz M, Kosinski M, Yarlas AS, et al. The minimally important difference of the Asthma Control Test. J Allergy Clin Immunol 124:719-723.e711, 2009.
22. Schatz M, Zeiger RS, Yang SJ, et al. Change in asthma control over time: Predictors and outcomes. J Allergy Clin Immunol Pract 2:59-64, 2014.
23. Tzortzaki EG, Georgiou A, Kampas D, et al. Long-term omalizumab treatment in severe allergic asthma: The South-Eastern Mediterranean real-life experience. Pulm Pharmacol Ther 25:77-82, 2012.
24. Centers for Disease Control and Prevention, Asthma Control: Improving Quality of Life, and Reducing Deaths and Costs. Available from: http://www.cdc.gov/asthma/aag/2010/overview.html. Accessed April 2, 2015.
25. Slejko JF, Ghushchyan VH, Sucher B, et al. Asthma control in the United States, 2008-2010: Indicators of poor asthma control. J Allergy Clin Immunol 133:1579-1587, 2014.
26. Chen H, Eisner MD, Haselkorn T, and Trzaskoma B. Concomitant asthma medications in moderate-to-severe allergic asthma treated with omalizumab. Respir Med 107:60-67, 2013.